Last reviewed · How we verify

Combined Acetaminophen and Ibuprofen

Washington University School of Medicine · Phase 3 active Small molecule

This combination drug reduces pain and fever by inhibiting cyclooxygenase enzymes (via ibuprofen) and modulating central pain pathways (via acetaminophen) simultaneously.

This combination drug reduces pain and fever by inhibiting cyclooxygenase enzymes (via ibuprofen) and modulating central pain pathways (via acetaminophen) simultaneously. Used for Acute pain management, Fever reduction.

At a glance

Generic nameCombined Acetaminophen and Ibuprofen
Also known asCombined regimen
SponsorWashington University School of Medicine
Drug classFixed-dose combination analgesic/antipyretic
TargetCOX-1, COX-2 (ibuprofen component); unclear central target (acetaminophen component)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Acetaminophen and ibuprofen work through complementary mechanisms: ibuprofen is a non-selective COX inhibitor that reduces prostaglandin synthesis peripherally and centrally, while acetaminophen's exact mechanism remains incompletely understood but involves central nervous system pain modulation and possible COX-3 inhibition. The combination may provide enhanced analgesic and antipyretic effects with potentially lower individual doses of each agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: